#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.
How Incretin Drugs Affect the Heart
A new review finds heart benefits from incretin drugs like tirzepatide and retatrutide involve pathways beyond blood sugar control.
Incretin Drugs and the Sarcopenia Question
A new review argues that incretin drugs such as tirzepatide and semaglutide need built-in muscle monitoring alongside fat-loss tracking.
Novo sues Lilly over GLP-1 ad claims
Novo Nordisk sued Eli Lilly over GLP-1 ads it says compare Zepbound with lower-dose Wegovy. Here is what the false-advertising suit alleges.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.
Tirzepatide and Oral Contraceptives
A new review asks whether tirzepatide's slowed digestion could also blunt oral progestogens used beyond birth control pills.
Tirzepatide vs GLP-1RAs and IBD risk
A US propensity-matched study found tirzepatide linked to fewer IV steroid courses than other GLP-1 drugs among patients who already have IBD.
CT130: A GLP-1 Drug Built to Take Breaks
CT130 is a semaglutide-derived GLP-1 drug tested so far in mice and monkeys, not humans, built around scheduled drug-free intervals.
Why Dying Liver Cells Drive MASH
A 2026 review explains how cell death fuels MASH, the liver disease semaglutide became the first FDA-approved drug to treat.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
Semaglutide and tirzepatide for MASH
Semaglutide now has FDA approval for MASH liver fibrosis, and tirzepatide's phase 2 data suggests a stronger signal is coming.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.